Advanced search×

Clinical Therapeutics

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Gale, Ingenta, Rcgp, and Sciencedirect from 1995

  1. Influence of CYP3A4 Induction/Inhibition on the Pharmacokinetics of Vilazodone in Healthy Subjects.

    Clinical Therapeutics 36(11):1638 (2014) PMID 25236915

    These results suggest that up to a 50% decrease of vilazodone dosage should be considered when it is given in combination with strong CYP3A4 inhibitors; conversely, increasing the vilazodone dosage up to a maximum of 80 mg/d should be considered when it is given in combination with strong CYP3A4 ind...
  2. What is depression and who is in depression studies?

    Clinical Therapeutics 36(11):1483 (2014) PMID 25455928

  3. Cost-Utility Analysis of Oral Anticoagulants for Nonvalvular Atrial Fibrillation Patients at the Police General Hospital, Bangkok, Thailand

    Clinical Therapeutics 36(10):1389 (2014) PMID 25267360

    Purpose The genetic polymorphism was one of the major considerations for adjusting doses of warfarin in Thai individuals. As a result, new oral anticoagulants (NOACs) were introduced to achieve therapeutic goals in stroke prevention in atrial fibrillation (SPAF) patients. However...
  4. Table of Contents
    Author(s) unavailable

    Clinical Therapeutics 36(10):A4 (2014)

  5. Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of i...

    Clinical Therapeutics 36(8):1182 (2014) PMID 24996489

    We randomly assigned 122 patients with CKD and dyslipidemia to 1 of 2 drug administration groups: morning administration of CR simvastatin 20 mg (test group) and evening administration of IR simvastatin 20 mg (control group). After 8 weeks, the treatment outcomes and adverse effects of the 2 treatme...
  6. Relationship between diclofenac dose and risk of gastrointestinal and cardiovascular events: meta-regression based on two systematic literat...

    Clinical Therapeutics 36(6):906 (2014) PMID 24863260

    We used studies identified in 2 recently published systematic reviews of observational studies that examined the risks of major GI and CV events associated with the use of oral NSAIDs. We developed meta-regression models, considering dose as a continuous measure, to estimate the risks of major GI an...
  7. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.

    Clinical Therapeutics 36(3):368 (2014) PMID 24534654

    We analyzed scenarios for different age groups, sexes, and SBP reductions. Specifically, SBP reductions due to hydrochlorothiazide (HCT) 25 mg and hypothetical reductions with HCT 12.5 mg-losartan 50 mg combination were assumed. Parameter uncertainty was assessed through a probabilistic sensitivity...
  8. Serum 25-hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with a high risk for fracture.

    Clinical Therapeutics 36(2):225 (2014) PMID 24462224

    Our aim was to explore the role of vitamin D status on QOL score in osteoporosis with high fracture risk. Patients were osteoporotic women aged ≥70 years and with ≥1 risk factor for incident fracture, namely prevalent osteoporotic fracture, bone mineral density (BMD) >-3.0 SD of young adult mean, or...
  9. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.

    Clinical Therapeutics 36(1):70 (2014) PMID 24315802

    Intravenous (IV) iron is the treatment of choice for iron-deficiency anemia (IDA) in patients with dialysis-dependent chronic kidney disease (DD-CKD). However, IV iron products have been associated with serious adverse events (SAEs), including anaphylactoid reactions. Ferumoxytol is an IV iron prepa...
  10. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.

    Clinical Therapeutics 35(12):1909 (2013) PMID 24238790

    New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment in progression-free survival (PFS) ranging from 2 to 6 months. Compared with best supportive care, everolimus demonstrated an additional PFS of 3 months in patients with mRCC whose disease had progressed on suni...